Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Robots make it to the healthcare conference panel, reflecting the future potential of technology
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
The campaign seeks to raise awareness about hypertension while emphasising the significance of managing blood pressure for a healthier lifestyle
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Subscribe To Our Newsletter & Stay Updated
